UBE2L3 anticorps (AA 81-154) (Cy5.5)
-
- Antigène Voir toutes UBE2L3 Anticorps
- UBE2L3 (Ubiquitin-Conjugating Enzyme E2L 3 (UBE2L3))
-
Épitope
- AA 81-154
-
Reactivité
- Humain
-
Hôte
- Lapin
-
Clonalité
- Polyclonal
-
Conjugué
- Cet anticorp UBE2L3 est conjugé à/à la Cy5.5
-
Application
- Western Blotting (WB), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p))
- Réactivité croisée
- Humain
- Homologie
- Mouse,Rat,Cow,Sheep,Horse,Rabbit,Zebrafish
- Purification
- Purified by Protein A.
- Immunogène
- KLH conjugated synthetic peptide derived from human Ube2L3
- Isotype
- IgG
- Top Product
- Discover our top product UBE2L3 Anticorps primaire
-
-
- Indications d'application
-
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200 - Restrictions
- For Research Use only
-
- Format
- Liquid
- Concentration
- 1 μg/μL
- Buffer
- Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
- Agent conservateur
- ProClin
- Précaution d'utilisation
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
- Stock
- -20 °C
- Stockage commentaire
- Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
- Date de péremption
- 12 months
-
- Antigène
- UBE2L3 (Ubiquitin-Conjugating Enzyme E2L 3 (UBE2L3))
- Autre désignation
- Ube2L3 (UBE2L3 Produits)
- Synonymes
- anticorps E2-F1, anticorps L-UBC, anticorps UBCH7, anticorps UbcM4, anticorps C79827, anticorps Ubce7, anticorps ube2l3, anticorps wu:fc22h11, anticorps zgc:86727, anticorps UBE2L3, anticorps ube2l3l, anticorps wu:fb38h03, anticorps ubiquitin conjugating enzyme E2 L3, anticorps ubiquitin-conjugating enzyme E2L 3, anticorps ubiquitin-conjugating enzyme E2L 3a, anticorps ubiquitin conjugating enzyme E2 L3 S homeolog, anticorps ubiquitin-conjugating enzyme E2L 3b, anticorps UBE2L3, anticorps Ube2l3, anticorps ube2l3a, anticorps ube2l3.S, anticorps ube2l3b
- Sujet
-
Synonyms: E2 F1, E2-F1, L UBC, L-UBC, UB2L3_HUMAN, UBCE7, UbcH7, UbcM4, Ube2l3, Ubiquitin carrier protein L3, Ubiquitin conjugating enzyme E2 L3, Ubiquitin protein ligase L3, Ubiquitin-conjugating enzyme E2 L3, Ubiquitin-conjugating enzyme E2-F1, Ubiquitin-protein ligase L3.
Background: The ubiquitin (Ub) pathway involves three sequential enzymatic steps that facilitate the conjugation of Ub and Ub-like molecules to specific protein substrates. The first step requires the ATP-dependent activation of the Ub C-terminus and the assembly of multi-Ub chains by the Ub-activating enzyme known as the E1 component. The Ub chain is then conjugated to the Ub-conjugating enzyme (E2) to generate an intermediate Ub-E2 complex. The Ub-ligase (E3) then catalyzes the transfer of Ub from E2 to the appropriate protein substrate. UBE2E1 and UBE2L3, also designated UBCH6 and UBCH7 respectively in human, are E2 conjugating enzymes that interact with various proteins. Specifically, UBE2E1 interacts with the tumor suppressor protein TSSC5. UBE2L3 has been shown to mediate c-fos degradation, NF-kB maturation, human papilloma virus-mediated p53 and Myc protein degradation.
- ID gène
- 7332
-